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Selected Mutations Reveal New Intermediates in the Biosynthesis 
of Mupirocin and the Thiomarinol Antibiotics  
Shu-Shan Gao,#  Luoyi Wang,# Zhongshu Song, Joanne Hothersall, Elton R. Stevens, Jack Connolly, 
Peter J. Winn, Russell J. Cox, Matthew P. Crump, Paul R. Race, Christopher M. Thomas, Thomas J. 
Simpson* and Christine L. Willis*  
Abstract: Mupirocin and the thiomarinols are assembled on similar 
polyketide/fatty acid backbones and exhibit potent antibiotic activity 
against MRSA. They both contain a tetra-substituted tetrahydropyran 
(THP) ring essential for biological activity. Mupirocin is a mixture of 
pseudomonic acids (PAs). Isolation of the novel mupirocin P 
containing a 7-hydroxy-6-ketoTHP from a mupP strain and 
chemical complementation experiments confirm that the first step in 
the conversion of PA-B to the major product PA-A is oxidation at C-6. 
In addition, nine novel thiomarinol (TM) derivatives with different 
oxidation patterns decorating the central THP core have been 
isolated from gene deletion (tmlF). These metabolites are in accord 
with the THP ring formation and elaboration in thiomarinol following 
a similar order to that found in mupirocin biosynthesis, despite 
lacking some of the equivalent genes. Novel mupirocin-thiomarinol 
hybrids have been synthesised using mutasynthesis.  
Thiomarinols (1-6) are an unusual group of hybrid antibiotics 
produced by the marine bacterium Pseudoalteromonas sp. 
SANK73390 (Figure 1).[1] They combine close analogues of the 
clinically important agent, mupirocin (a mixture of pseudomonic 
acids, PA  A–C, 7-9)[2]  with the pyrrothine subunit of the 
holomycin class of antibiotics. Both thiomarinols and mupirocin 
display potent activity against MRSA (methicillin-resistant 
Staphylococcus aureus),[3] and belong to the trans-AT class of 
modular polyketide-derived antibiotics.[4] The mup biosynthetic 
gene cluster was one of the first of this class to be discovered,[5]  
but there are now more than 20 at least partially characterised, 
with many others known from genomic sequences.[4] 
Thiomarinols can be regarded as comprising three main 
elements: a highly functionalised polyketide-derived acid, which 
is esterified by 8-hydroxyoctanoic acid, which itself forms an 
amide with the bicyclic amino acid-derived pyrrothine. The major 
components TM-A 1 and PA-A 7 differ in the lack of a 10,11-
epoxide, the presence of a 4-hydroxyl, a C8 rather than a C9 fatty 
acid, and the pyrrothine in TM-A.[6]  
The 6,7-dihydroxytetrahydropyran (THP) ring is necessary for 
the biological activity of mupirocin and thiomarinol, so 
elucidation of the biosynthetic mechanisms for ring formation 
and further modifications to the 6,7-diol is important. Mutational 
analysis of mupirocin biosynthesis showed somewhat counter-
intuitively: (a) that the 8-hydroxyl of PA-B 8 has to be lost not 
gained, with feeding experiments confirming that PA-B is an 
intermediate in the biosynthesis of PA-A 7[7] and (b) that PA-C 9 
is the product of a parallel pathway that branches from the main 
pathway (to PA-A) following failure to undergo epoxidation of the 
10,11-double bond.[8] Analyses of mutant strains[9] indicate that 
putative biosynthetic precursor 12 (Scheme 1) is cyclised and 
esterified to give PA-B with the tetrahydropyran ring. 
Furthermore identification of minor metabolites with C5 and C7 
fatty acid side-chains are in accord with elaboration of the 9-
hydroxynonanoic acid moiety occurring by initial addition of 3-
hydroxypropionate followed by 3 successive MmpB-mediated 
chain elongations.[7b]  
 
 
 
 
Figure 1. Selected thiomarinols and pseudomonic acids. 
 
 
New insights into the mechanism of PA-B to PA-A 
conversion – MupP acts as a dehydratase.  
Conversion of PA-B 8 to PA-A 7, formally removal of the 8-
hydroxy, has been shown to require MupU (CoA-ligase) and 
MacpE (ACP), MupO (P450), MupV (see below), MupC (enoate 
reductase) and MupF (ketoreductase) via the isolated 
intermediates mupirocin C1 14 and mupirocin F1 15, as shown 
in Scheme 1. Deletion of any of mupO, mupU, mupV or macpE 
all gave PA-B 8 as the major product along with the 
macrolactone 10.[8] The first step in the conversion of PA-B 8 to 
PA-A 7 is MupU catalysed ligation of PA-B to MacpE (Scheme 
1) followed by oxidation (MupO). However, no metabolite 
corresponding to the putative -hydroxyketone product 13 of 
MupO had been detected. Isolation and identification of these 
epoxide-containing metabolites is challenging as they are prone 
to rearrangements but are key to elucidating the remaining 
biosynthetic steps from PA-B to PA-A. Indeed PA-A itself is 
limited to mainly topical applications due to its instability in 
serum.[3]  
Our first goal was to establish the proposed 7-hydroxy-6-ketone 
13 as a biosynthetic intermediate to PA-A. Analysis of a mupP 
strain revealed a major metabolite with MW 514 in accord with 
13, but it was unstable and gave rearrangement products. 
Further analysis of this mutant, however, using Sephadex LH-20 
fractionation of the crude extract has allowed isolation of the 
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product and detailed 1D and 2D NMR analysis (see Supporting 
Information) confirms the structure of this key intermediate, 
which is now named mupirocin P (13). 
 
 
Scheme 1.  MupP acts as a dehydratase in mupirocin biosynthesis 
We have shown previously that the OR domain of MmpE is 
responsible for epoxidation.[8] Thus a double mutant, 
mmpEOR/mupP strain was constructed. Gratifyingly, this 
produces the less labile desepoxy-mupirocin P 16 as the main 
metabolite along with a small amount of desepoxy-PA-B 17 
(Figure 2). MupP had not been previously assigned a function. 
Bioinformatic analysis indicates that it belongs to the 
glyoxalase/bleomycin resistance protein/dioxygenase 
superfamily but appears to act here overall as a dehydratase to 
give enol-ketone 14 (Scheme 1).  
 
 
 
Figure 2. HPLC trace of crude extract of the mmpEOR/mupP double 
mutant strain of P. fluorescens NCIMB 10586 
Previous mutasynthesis studies on mupirocin biosynthesis[8] 
showed that PA-B 8, mupirocin C1 14 and mupirocin F1 15 were 
all efficiently (15-50%) converted to PA-A 7 by mutant strains of 
P. fluorescens blocked in earlier parts of the pathway, thus 
confirming their role as intermediates in mupirocin biosynthesis.  
To investigate if the 7-hydroxy-6-ketone is also a true 
intermediate on the pathway, desepoxy-mupirocin P 16, isolated 
from the mmpEOR/mupP strain, was fed to cultures of the 
mmpEORmupW strain and LC-MS showed a peak with the 
same retention time as desepoxy-mupirocin P but with MW 484. 
The metabolite was isolated and NMR revealed that PA-C had 
been produced confirming that desepoxy-mupirocin P is indeed 
an intermediate in PA-C 9 biosynthesis (Scheme 2).  
Reanalysis of the MupV amino acid sequence, which had 
previously been identified as a putative oxidoreductase, 
revealed a second domain with ca. 30% sequence identity to 
many Pseudomonas hydrolases. These contain a GXCXG 
consensus sequence where cysteine replaces the more 
common nucleophilic serine and includes an amino transferase 
involved in shuffling intermediates between thiolation domains in 
the syringomycin biosynthetic pathway in Pseudomonas 
syringae.[10]  Thus MupV may act as a thioesterase or perhaps in 
some related ACP transfer capacity. Previously deletion of 
mupV had provided few clues as this yielded PA-B 8 as the 
major product.[9c]  However, in this study, feeding desepoxy-
mupirocin P 16 to the mupV strain gave PA-C in accord with a 
Mup V activity being required before MupP leading to mupirocin 
P 13 (and desepoxy-mupirocin P 16) for successive dehydration 
(MupP) and reductions catalysed by MupC and MupF to PA-A 7 
(and PA-C 9) (Schemes 1 and 2). 
 
 
 
Scheme 2.  Feeding 16 to either mmpEOR/mupW or mupV strains gives 
PA-C 9. 
 Thiomarinol biosynthesis 
The thiomarinol (tml) biosynthetic gene cluster was identified via 
complete genome sequencing of SANK73390, which was found 
to harbour a 97 kb plasmid consisting almost entirely of the 
thiomarinol biosynthetic genes.[11] These include multimodular 
trans-AT PKSs (tmpA, C and D), a putative FAS (tmpB) and 
associated tailoring and resistance genes (tmlA-Z) most of which 
exhibit high homology to counterparts in the mupirocin (mup) 
cluster (Figure S1). A non-ribosomal peptide synthetase (NRPS) 
linked to a set of tailoring enzymes (holA-H) similar to that 
recently shown to control holomycin biosynthesis in 
Streptomyces clavuligerus is also present.[12] We have produced 
mutant strains of SANK73390 in which the PKS and NRPS parts 
of the cluster have been insertionally deactivated. Analysis of 
WT, NRPS and tmlU mutant strains led to the isolation of 
marinolic acids A 18, A6 20, and A4 21 lacking the pyrrothine 
(Figure 3).[13] In the minor components marinolic acids A6 and A4 
the octanoate moiety of marinolic acid A has been replaced by 
hexanoate and butanoate respectively. Using a combination of 
genetic and isotopic labelling studies, we showed that the 8-
hydroxyoctanoic acid side-chain is generated via successive 
chain extensions of a C4 precursor (4-hydroxybutyrate) derived 
from succinate, to give marinolic acids 18, 20 and 21 and that 
pyrrothine is assembled from two molecules of cysteine (HolA-D) 
prior to intact incorporation into thiomarinol.[13] It has recently 
been shown that TmlU acts as a substrate selective CoA ligase 
that activates marinolic acid as a thioester which in turn is the 
substrate for amide formation catalysed by the acyl transferase 
HolE.[14]  Analysis of the PKS mutant revealed a series of acyl-
pyrrothines designated as xenorhabdins.[13] 
Marinolic acid A 18 has a similar structure to PA-A 7 but lacks 
the epoxide and has an additional 4-hydroxyl group. The tml 
pathway, however has only some of the homologues of the mup 
genes, viz. tmlW, T, O, P, C and F, but homologues of the stand 
alone ACP macpE, mupU and mupV are missing. The absence 
of these genes from the tml cluster raises the question of how 
the same overall conversion can be achieved with an apparently 
simpler gene set. We now report results which indicate that a 
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similar set of intermediates are indeed involved in THP ring 
formation and further modification in both mupirocin and 
thiomarinol biosynthesis. 
 
 
 
Figure 3. Marinolic acids and acyl-pyrrothine metabolites isolated from WT 
and mutant strains of Pseudoalteromonas sp SANK73390 
Chemical investigation of ΔtmlF- late stage biosynthetic 
steps.  
Deletion of mupF (7-ketoreductase) in P. fluorescens releases a 
number of intermediates including mupirocin C1 14 and PA-B 8 
and related shunt products in addition to mupirocin F1 15 
(Scheme 1).[9b] TmlF, shows 33% amino acid sequence identity 
to MupF so it is likely to act as a 7-ketoreductase as does MupF 
in the final step in mupirocin biosynthesis, which converts 
mupirocin F1 15 to the dihydroxytetrahydropyran PA-A 7. Thus 
deletion of tmlF could release more intermediates and shunt 
products besides its own substrate analogous to the mupF 
deletion. 
 
 
 
Figure 4. Novel metabolites isolated from extracts of the ΔtmlF mutant of 
Pseudoalteromonas sp. SANK73390 
 
WT SANK73390 was cultivated on a modified marine broth 
medium (see SI for details) which significantly improved the 
production of the total thiomarinols. Using this medium, a yield of 
70–100 mg.L-1 TM-A 1 could be obtained, compared to 10-20 
mg.L-1 in previous studies.[6] Our aim was to carry out a set of 
gene KOs to parallel those carried out with mupirocin,[8,9]  but 
reverse genetics of SANK73390 proved to be problematic. We 
were however successful in making the key tmlF by the 
method previously reported[11] using approximately 500bp arms 
defining an in-frame deletion from aa 10 to aa 327 in TmlF.  
Analysis of extracts showed that as anticipated the 
production of thiomarinols A and C (1 and 2, Figure 1) was 
completely abolished, but the xenorhabdin acyl-pyrrothine 
metabolites were generated as normal. Further analysis of the 
HPLC trace indicated that various new thiomarinol-related 
metabolites were present albeit in minor amounts, 0.1 - 1.2 
mg.L-1 (Figure 4). A major product among those minor 
metabolites was identified as 8-hydroxy-thiomarinol C 22. Its 
structure, and that of other metabolites reported herein, were 
determined by full NMR analysis and HR-ESI-MS (see SI for 
details). The presence of an 8-hydroxy-THP ring as in PA-B 8 
suggests that both biosynthetic pathways possess analogous 
pyran ring closing mechanisms, and will require similar 
mechanisms for removal of the 8-OH function. The only previous 
thiomarinol derivative reported to contain an 8-hydroxyl is TM-G 
6 (as a very minor metabolite of WT SANK73390),[1c] but it lacks 
both the 4 and 6-hydroxyls. We have not observed 6 in any of 
our studies, and its structure remains to be confirmed. Further 
detailed analysis of minor components resulted in the isolation of 
metabolites 23–30. These metabolites form two structurally 
distinct groups. The first consists of 6,7- diketothiomarinol C 23, 
analogous to mupirocin C1 14 isolated from ∆mupC, its 4-
hydroxy analogue 24, and 25 a 6,7-diketo analogue of marinolic 
acid A6 lacking the 4-hydroxyl and the pyrrothine. These all exist 
as the enol-ketone tautomers shown. The second group 
possesses the 6-hydroxy-7-keto THP ring (7-keto-thiomarinol C 
26 and its 4-hydroxy analogue 27) similar to mupirocin F1 15 
isolated from ∆mupF, and products (28–30) derived from 26 and 
27 by keto-enol tautomerism and/or epimerisation. This is 
consistent with a biosynthetic sequence to thiomarinol C 2 being 
similar to mupirocin after the formation of the 8-hydroxyTHP ring. 
Interestingly, the 4-hydroxy analogue of 8-hydroxy-thiomarinol C 
was not detected.  
 
Chemical Complementation Experiments 
When PA-A 7 was fed to the PKS mutant strain of SANK73390 
in which all of the tailoring genes are intact, it was metabolised 
with both 4-hydroxylation and/or pyrrothine addition taking place 
to give the novel mupirocin/thiomarinol hybrid molecules 31-33 
(Scheme 3).[6,13] In this study we have investigated 
biotransformations of further substrates isolated from P. 
fluorescens and the products were isolated and fully 
characterised by spectroscopic methods.   
On feeding PA-C 9, with the mature 6,7-dihydroxypyran ring, the 
pyrrothine was added to give the novel metabolite 36 (MW 638) 
and 4-hydroxylation yielded 37 (MW 654) in similar amounts 
(Scheme 3). In contrast, feeding PA-B 8 or desepoxy-PA-B 17 
simply led to pyrrothine addition (34 and 35, respectively) and no 
C-4 hydroxylated metabolites were detected. Hence it is 
apparent that the presence of an 8-hydroxyl inhibits 4-
hydroxylation. 
Desepoxy-mupirocin P 16 was also fed to cultures of the PKS 
mutant giving the 3 metabolites, 35, 36 and 37 all of which had 
the pyrrothine added. Importantly it was evident that further 
processing of the THP ring had occurred leading to loss of the 8-
hydroxyl and keto-reduction giving the fully mature 6,7-
dihydroxylated product 36;  a minor product detected by LC-MS 
was the corresponding 4-hydroxylated metabolite 37. The 6,7,8-
trihydroxy metabolite 35 was formed via a keto-reduction and 
pyrrothine addition, but no loss of the 8-hydroxyl was observed.  
It is interesting to compare the metabolism of 8-hydroxyTHPs in 
P. fluorescens and Pseudoalteromonas. In the former desepoxy 
PA-B 17 (and PA-B 8) undergo efficient oxidation, dehydration 
and keto-reduction to give the bioactive 6,7-diols PA-C 9 (and 
PA-A 7). In contrast, in the PKS mutant of Pseudoalteromonas 
whilst further processing of the 6,8-dihydroxy-7-ketoTHP ring of 
desepoxy-mupirocin P 16 to the mature 6,7-dihydroxyTHP as 
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well as pyrrothine addition readily occurs, feeding the  6,7,8-
trihydroxy THP substrates 8 or 17, only pyrrothine addition was 
apparent. 
 
 
Scheme 3. Transformation of mupirocin analogues by the PKS mutant strain 
of Pseudoalteromonas SANK73390. 
 
Conclusions 
MupP has been identified as a dehydratase involved in 
mupirocin biosynthesis. The mupP strain of P. fluorescens was 
cultured and the novel 6-keto-7-alcohol, mupirocin P 13 was 
isolated and fully characterised. Results of chemical 
complementation studies feeding desepoxy-mupirocin P 16 to 
the mmpEOR/mupW strain blocked earlier in the biosynthetic 
pathway, are in accord with 16 being an intermediate in the 
biosynthesis of the bioactive 6,7-diol PA-C 9 (and the epoxy 
analogue mupirocin P 13 is deduced to be a biosynthetic 
precursor of PA-A 7). Hence the first step in conversion of PA-B 
8 to PA-A 7 is oxidation at C-6. Furthermore feeding 16 to the 
mupV strain gave PA-C in accord with MupV acting before 
MupP.  
Despite some divergencies in the gene clusters, the isolation of 
novel metabolites including 22, 23 and 26 from cultures of the 
tmlF mutant of SANK73390 point to some similarities in THP 
ring processing in both thiomarinol and mupirocin. Indeed, 
feeding desepoxy-mupirocin P 16 to cultures of the PKS mutant 
not only led to addition of the pyrrothine but also confirmed that 
further processing of the THP ring occurred giving 6,7-
dihydroxylated products 36 and 37. In contrast, feeding 
desepoxy-PA-B 17 to the PKS mutant strain simply led to 
addition of the pyrrothine and no THP modified products were 
detected.  PA-B 8 is efficiently converted to PA-A 7 by mutant 
strains of P. fluorescens blocked earlier in the biosynthetic 
pathway indicating an important difference between the two 
pathways.  
Differences are evident in the two gene clusters. Homologues of 
the mupirocin stand-alone ACP MacpE, along with MupU and 
MupV are missing in SANK73390. TmpB, however, contains 
extra KS and ACP domains as compared to MmpB which it is 
speculated may replace the apparently missing activities.[13] 
Thus the tetrahydropyran processing reactions occurring on 
intermediates bound to MacpE, may take place while bound to 
the additional ACP on TmpB, thus obviating the need for 
homologues of MacpE and MupU. The lack of ring processing of 
PA-B 8 and desepoxy-PA-B 17 fed to the PKS mutant of 
Pseudoalteromonas thus may be rationalised by an inability of 
these substrates to be loaded onto TmpB so providing key 
evidence to support our proposed pathway to the marinolic acids.  
Studies are in progress to fully understand the differences 
between the two pathways as well as to identify the genes for 4- 
and 6-hydroxylation in thiomarinol and 6-hydroxylation in 
mupirocin biosynthesis. 
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